Congenital heart malformations refer to structural abnormalities of the heart present at birth, often arising during fetal development. These conditions, also known as congenital heart defects (CHDs), can affect the heart's walls, valves, and blood vessels, disrupting the normal flow of blood. While some CHDs may have minimal impact on a person's health, others can be severe and require immediate medical attention. The causes of congenital heart malformations are diverse and may involve genetic factors, environmental influences, or a combination of both. Advances in medical technology have enabled early detection through prenatal screening, allowing for timely intervention and treatment. Treatment options vary depending on the specific defect and its severity, ranging from medication to surgical procedures. Despite these advancements, congenital heart malformations remain a significant global health concern, necessitating ongoing research and medical efforts to improve prevention, diagnosis, and management. Early detection and intervention can significantly enhance the quality of life for individuals with congenital heart defects, highlighting the importance of continued medical research and public awareness.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India